Mark Zuckerberg's AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report
What Happened: WhatsApp, with over 3 billion global users, has become a prime platform for various AI chatbots, including those from OpenAI and Perplexity, alongside Meta's own assistant, reported Business Insider. This intense competition could potentially hinder Meta AI's goal of becoming the default choice for its billions of users.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —
Notably, in the April earnings call, Meta's CEO, Mark Zuckerberg, revealed that WhatsApp is 'the largest surface that people use Meta AI on.'
WhatsApp, a primary battleground for consumer AI, is witnessing a surge in rival chatbots vying for user attention. Despite Meta AI being integrated into WhatsApp, the app's strong usage continues.
OpenAI, which brought ChatGPT to WhatsApp last year, is working to make AI more widely accessible. Meanwhile, Perplexity's chatbot, launched on WhatsApp this spring, experienced such overwhelming demand at launch that it briefly crashed.
These competing chatbots utilize the WhatsApp Business Platform, allowing them to reach WhatsApp's vast global audience without requiring Meta's direct approval. This is particularly beneficial in emerging markets such as India and Brazil, where WhatsApp is a primary communication tool.
Meta did not immediately respond to Benzinga's request for comment.Why It Matters: The rise of AI chatbots on WhatsApp comes at a time when Meta is facing challenges. Just a day before this report, WhatsApp was banned on U.S. House devices over transparency and encryption concerns, further complicating Meta's position.
However, Meta's WhatsApp is not without its potential. An analyst recently estimated that Meta could potentially generate over $10 billion in annual ad revenue from its WhatsApp messaging service by 2028, indicating that the platform still holds significant value for the company.
Benzinga's Edge Rankings place Meta Platforms in the 85th percentile for momentum and the 28th percentile for value, reflecting its strong performance in both areas. Check the detailed report here.
On a year-to-date basis, Meta stock surged 16.57%, according to data from Benzinga Pro.
Read Next:
Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential.
These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends
Image via ShutterstockUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Mark Zuckerberg's AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report originally appeared on Benzinga.com
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?
Warren Buffett has struck again – this time in healthcare's rubble. Berkshire Hathaway (NYSE: BRK.B) recently disclosed a five million share position in United Healthcare Group (NYSE: UNH), the nation's largest health insurer. The timing is quintessentially Buffett. UNH shares have plummeted more than 50% from their all-time highs, battered by regulatory pressures and industry headwinds. While most investors flee the carnage, the Oracle of Omaha is doing what he does best – hunting for value in the wreckage. But as with everything Buffett does, context matters. Putting Things in Perspective The United Healthcare position is estimated to be worth around US$1.6 billion based on Berkshire's five million share purchase. That's a sizable sum of money by any measure. Here's what you need to know: Berkshire Hathaway's stock portfolio is worth close to US$295 billion. Therefore, the UNH position is less than 0.6% of the company's overall stock holdings. In contrast, Berkshire's largest position is actually Apple (NASDAQ: AAPL), valued at US$65 billion – representing more than a fifth of the total stock portfolio. Put simply, while the United Healthcare investment grabbed headlines, it wouldn't be moving Berkshire's needle anytime soon. Beyond that, there's a crucial question: did Buffett actually make this call? The Real Decision Makers Every Berkshire Hathaway stock purchase gets dissected as if it came straight from Warren Buffett himself. But the Oracle doesn't fly solo anymore. Berkshire brought on Todd Combs in 2010, followed by Ted Weschler in 2012. Both serve as investment managers with significant autonomy. Initially, Buffett allocated US$2 billion to each manager. By 2017, that figure had quintrupled to US$10 billion per person. Given this structure, the US$1.6 billion UNH bet could be from either Combs or Weschler – not Buffett himself. Get Smart: Look before you leap Context matters when it comes to investing. If you jump in and buy shares without understanding the full picture, you could get hurt in the process. For Berkshire, even if the UnitedHealth investment doesn't work out, you won't see the company sweating over a position worth less than 0.6%. Does the same apply to you? That's food for thought if you decide to pull the trigger. Dive into the future of technology with our newest FREE report, 'The Rise of Titans.' Discover how the big 7 US tech stocks can be your ticket to huge long-term gains. Download your copy today and see how easy it is to supercharge your portfolio. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Chin Hui Leong owns shares of Apple and Berkshire Hathaway The post Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow? appeared first on The Smart Investor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
